About Microbion

Microbion is a clinical-stage pharmaceutical company developing a novel class of compounds for the treatment of difficult-to-treat infections, including chronic infections and antibiotic-resistant infections.

Microbion is dedicated to developing best-in-class, novel medicines that uniquely address key unmet medical needs and thereby provide physicians with durable, breakthrough options to improve and extend the lives of patients.

Microbion’s lead therapeutic candidate, MBN-101, is in clinical development for treatment of diabetic foot ulcer infection (Phase 2) and orthopedic device related infection (Phase 2).